CYP2D6 testing to predict response to tamoxifen in women with breast cancer: Pharmacogenomic

Tamoxifen, a selective estrogen receptor modulator, is the standard of care for premenopausal women with estrogen or progesterone receptor-positive breast cancer and a valid option for treating post-menopausal women. However, a substantial number of tamoxifen-treated patients relapse following surgi...

Descripción completa

Detalles Bibliográficos
Autores principales: Dahabreh, Issa, Terasawa, Teruhiko, Castaldi, Peter, Trikalinos, Thomas A
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Evidence on Genomic Tests
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940141/
https://www.ncbi.nlm.nih.gov/pubmed/20877451
http://dx.doi.org/10.1371/currents.RRN1176

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940141/
https://www.ncbi.nlm.nih.gov/pubmed/20877451
http://dx.doi.org/10.1371/currents.RRN1176

Ejemplares similares